Omeros Corporation: Business Overview, Financials & Competitive Analysis
Omeros Corporation scores 7/10 on the AskCyborg Cyborg Score (Strong). First-mover advantage in lectin pathway inhibition with near-term commercial revenue potential offsets biotech execution risk. Omeros achieved a major regulatory milestone with FDA approval of its first-in-class YARTEMLEA therapy in December 2025, immediately entering commercialization phase. The company has strengthened its balance sheet through strategic debt restructuring and maintains a.
What is Omeros Corporation's industry? Omeros Corporation (omeros.com) operates in Biopharmaceuticals - Specialty/Orphan Drugs. AskCyborg classifies Omeros Corporation under Biopharmaceuticals - Specialty/Orphan Drugs in its company registry.
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immun...
Cyborg Score thesis
First-mover advantage in lectin pathway inhibition with near-term commercial revenue potential offsets biotech execution...
Read the full analyst-debate transcript →Get the Latest Omeros Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeOmeros Corporation Overview
Pro stress-test →Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. The FDA approved YARTEMLEA® (narsoplimab-wuug) in December 2025 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is the first and only approved lectin pathway inhibitor.
Strategic Profile
Pro stress-test →With a U.S. launch planned for January 2026, the company is focused on ensuring rapid, reliable access to YARTEMLEA. Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), a MASP-3 inhibitor in clinical development for PNH and other alternative pathway indications. The company maintains a diversified pipeline including OMS1029, OMS527 for cocaine use disorder, and immuno-oncology programs.
Competitive Landscape
Pro stress-test →Omeros operates in the specialized complement pathway disorder market with first-mover advantage in lectin pathway inhibition. Key competitors in complement-mediated disease space include Alexion (AstraZeneca), Achillion (Alexion subsidiary), and Akcea Therapeutics. The broader immunology market is competitive but TA-TMA represents an orphan indication with limited treatment options prior to YARTEMLEA's approval, reducing direct competition in the near term.
Industry Context
Omeros Corporation operates in Biopharmaceuticals - Specialty/Orphan Drugs.
Key facts
Founded: 1994 · Headquarters: Seattle, Washington